You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER
SBC: PAPGENE, INC. Topic: NCIThis proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
PLATFORM FOR NEUROCOGNITIVE EVALUATION AND MONITORING
SBC: ENFORMIA INC. Topic: NCICurrent standardized neuropsychological tests are based on decades old paper and pencil methods They lack reliability sensitivity specificity repeatability and require trained neuropsychologists to administer them Their administration in clinical and research settings result in high cost complexity and inconsistent results There is a need and a commercial opportunity for an extensible co ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Yeast based Immunotherapy against Clostridium difficile Infection
SBC: FZATA INC Topic: NIAIDAbstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
An RNA targeted platform for anti flavivirus drug discovery
SBC: Ribometrix LLC Topic: NIAIDSUMMARY Emerging and re emerging mosquito borne flaviviruses cause widespread mortality morbidity and economic burden Options for prevention and treatment of mosquito borne flaviviruses are limited Flavivirus vaccines face unique development challenges no antiviral therapies are available and the mosquito vectors have proven difficult to eradicate Despite vaccines against Yellow Fever and J ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Strategies to Improve Production of a Full Length Native HIV Env Spike
SBC: CODEX BIOSOLUTIONS Topic: RProject Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Serotype independent therapeutic vaccine for Streptococcus pneumoniae
SBC: Integrated Biotherapeutics, Inc. Topic: RIn the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of user-friendly fluorescence based assays for marine toxins
SBC: SEATOX RESEARCH INC Topic: 113ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Peptide based tool for the rapid isolation of quiescent monocytes from peripheral blood
SBC: AFFINERGY, LLC Topic: 102SUMMARY ABSTRACT Dendritic cell DC therapy represents a new and promising immunotherapeutic approach for treatment of advanced stage cancers with DC vaccines already approved for use in advanced prostate cancer and more than DC based vaccines in the clinical development pipeline for other cancers In particular the US market for cancer vaccines including DC based vaccines is set to expan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development and Validation of a Collaborative Web-Based Quantitative Imaging and Dosimetry System for Radiopharmaceutical Therapy
SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC Topic: NCIRadiopharmaceutical therapyRPTis an emerging cancer treatment that delivers radiation directly to cancer cellsThe recent FDA approval ofRa Xofigotmfor resistant metastatic prostate cancer and its commercial success provides an example of the therapeutic and commercial potential of this modalityIn additiondrug companies have large libraries of targets and targeting moleculesProgress in chelators an ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health